GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » Equity-to-Asset

Bone Biologics (Bone Biologics) Equity-to-Asset : 0.78 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bone Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2.91 Mil. Bone Biologics's Total Assets for the quarter that ended in Dec. 2023 was $3.74 Mil.

The historical rank and industry rank for Bone Biologics's Equity-to-Asset or its related term are showing as below:

BBLG' s Equity-to-Asset Range Over the Past 10 Years
Min: -382.84   Med: -3.67   Max: 0.99
Current: 0.78

During the past 10 years, the highest Equity to Asset Ratio of Bone Biologics was 0.99. The lowest was -382.84. And the median was -3.67.

BBLG's Equity-to-Asset is ranked better than
71.38% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs BBLG: 0.78

Bone Biologics Equity-to-Asset Historical Data

The historical data trend for Bone Biologics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics Equity-to-Asset Chart

Bone Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -382.84 - 0.99 0.70 0.78

Bone Biologics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.41 0.75 0.76 0.78

Competitive Comparison of Bone Biologics's Equity-to-Asset

For the Medical Devices subindustry, Bone Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bone Biologics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bone Biologics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bone Biologics's Equity-to-Asset falls into.



Bone Biologics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bone Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.906/3.738
=

Bone Biologics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.906/3.738
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bone Biologics  (NAS:BBLG) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Bone Biologics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bone Biologics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bone Biologics (Bone Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Executives
Deina H Walsh officer: Chief Financial Officer 175, MAY STREET, EDISON NJ 08837
Jeff Frelick officer: Chief Operating Officer 1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd 10 percent owner 4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle director 481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey director, 10 percent owner, officer: Chairman of the Board 4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey director 4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour 10 percent owner 269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc. director 175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu director 2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R. director, officer: CEO and President 106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram director 12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad director 132 S. MAPLE DR., BEVERLY HILLS CA 90212